Changes in Drug Clinical Trials of Thyroid Diseases in China, 2009–2022

References

• Deng Y, Li H, Wang M, et al. Global burden of thyroid cancer from 1990 to 2017. JAMA Netw Open. 2020;3(6):e208759. doi:10.1001/jamanetworkopen.2020.8759
   PubMed Web of Science ®Google Scholar
• Wang J, Yu F, Shang Y, et al. Thyroid cancer: incidence and mortality trends in China, 2005-2015. Endocrine. 2020;68(1):163–173. doi:10.1007/s12020-020-02207-6
   PubMed Web of Science ®Google Scholar
• Li Y, Teng D, Ba J, et al. Efficacy and Safety of Long-Term Universal Salt Iodization on Thyroid Disorders: epidemiological Evidence from 31 Provinces of Mainland China. Thyroid. 2020;30(4):568–579. doi:10.1089/thy.2019.0067
   PubMed Web of Science ®Google Scholar
• Shan Z, Chen L, Lian X, et al. Iodine Status and Prevalence of Thyroid Disorders After Introduction of Mandatory Universal Salt Iodization for 16 Years in China: a Cross-Sectional Study in 10 Cities. Thyroid. 2016;26(8):1125–1130. doi:10.1089/thy.2015.0613
   PubMed Web of Science ®Google Scholar
• Su X, Wang H, Zhao N, et al. Trends in innovative drug development in China. Nat Rev Drug Discov. 2022;21(10):709–710. doi:10.1038/d41573-022-00077-3
   PubMed Web of Science ®Google Scholar
• Chen H, Zhou Y, Han X, et al. The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): a systematic review. Lancet Reg Health West Pac. 2021;8:100097. doi:10.1016/j.lanwpc.2021.100097
   PubMedGoogle Scholar
• Zhong Q, Tao Y, Chen H, et al. The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020. Lancet Reg Health West Pac. 2021;11:100151. doi:10.1016/j.lanwpc.2021.100151
   PubMedGoogle Scholar
• Song L, Jia Y, Ran S, et al. Current situation of pediatric clinical trials in China: focus on trials for drug marketing application and administrative approval. BMC Pediatr. 2022;22(1):144. doi:10.1186/s12887-022-03208-2
   PubMed Web of Science ®Google Scholar
• Li N, Huang HY, Wu DW, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review. Lancet Oncol. 2019;20(11):e619–e26. doi:10.1016/S1470-2045(19)30491-7
   PubMed Web of Science ®Google Scholar
• La Vecchia C, Negri E. Thyroid cancer: the thyroid cancer epidemic - overdiagnosis or a real increase? Nat Rev Endocrinol. 2017;13(6):318–319. doi:10.1038/nrendo.2017.53
   PubMed Web of Science ®Google Scholar
• Priya SR, Dravid CS, Digumarti R, et al. Targeted therapy for medullary thyroid cancer: a review. Front Oncol. 2017;7:238. doi:10.3389/fonc.2017.00238
   PubMed Web of Science ®Google Scholar
• Opinions on Deepening the Reform of the Evaluation and Approval System and Encouraging the Innovation of Pharmaceutical and Medical Devices; 2017. Available from: http://www.gov.cn/xinwen/2017-10/08/content_5230105.htm?from=groupmessage&isappinstalled=0. Accessed July 10, 2023.
   Google Scholar
• Opinions on Reforming the Evaluation and Approval System of Pharmaceutical and Medical Devices; 2015. Available from: http://www.gov.cn/zhengce/content/2015-08/18/content_10101.htm. Accessed July 10, 2023.
   Google Scholar
• Announcement of the National Medical Products Administration on adjusting the approval process for drug clinical trial evaluation; 2018. Available from: https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/ywlchshyjgrdgg/20180727172901286.html. Accessed July 10, 2023.
   Google Scholar
• Opinions on the evaluation of consistency of quality and efficacy of generic drugs; 2016. Available from: http://www.gov.cn/zhengce/content/2016-03/05/content_5049364.htm. Accessed July 10, 2023.
   Google Scholar
• Filetti S, Durante C, Hartl DM, et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol. 2022;33(7):674–684. doi:10.1016/j.annonc.2022.04.009
   PubMed Web of Science ®Google Scholar
• Attwood MM, Fabbro D, Sokolov AV, et al. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021;20(11):839–861. doi:10.1038/s41573-021-00252-y
   PubMed Web of Science ®Google Scholar
• Nagura S, Katoh R, Miyagi E, et al. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. Hum Pathol. 2001;32(1):10–17. doi:10.1053/hupa.2001.21139
   PubMed Web of Science ®Google Scholar
• Prabhu M, Shakya S, Ballal S, et al. RET gene mutation analysis and long-term clinical outcomes of medullary thyroid cancer patients. Nucl Med Commun. 2020;41(11):1136–1142. doi:10.1097/MNM.0000000000001264
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, Phase 3 trial. Lancet. 2014;384(9940):319–328. doi:10.1016/S0140-6736(14)60421-9
   PubMed Web of Science ®Google Scholar
• Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–3646. doi:10.1200/JCO.2012.48.4659
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630. doi:10.1056/NEJMoa1406470
   PubMed Web of Science ®Google Scholar
• Nygaard B, Jensen EW, Kvetny J, et al. Effect of combination therapy with thyroxine (T4) and 3,5,3’-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur J Endocrinol. 2009;161(6):895–902. doi:10.1530/EJE-09-0542
   PubMed Web of Science ®Google Scholar
• Jonklaas J, Bianco AC, Cappola AR, et al. Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: a Consensus Document. Eur Thyroid J. 2021;10(1):10–38. doi:10.1159/000512970
   PubMed Web of Science ®Google Scholar
• Castellana M, Castellana C, Giovanella L, et al. Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy? Endocrine. 2020;67(2):281–290. doi:10.1007/s12020-019-02185-4
   PubMed Web of Science ®Google Scholar
• Ducharme M, Scarsi C, Bettazzi E, et al. A Novel Levothyroxine Solution Results in Similar Bioavailability Whether Taken 30 or Just 15 Minutes Before a High-Fat High-Calorie Meal. Thyroid. 2022;32(8):897–904. doi:10.1089/thy.2021.0604
   PubMed Web of Science ®Google Scholar
• Astwood EB, Vanderlaan WP. Treatment of hyperthyroidism with propylthiouracil. Ann Intern Med. 1946;25(5):813–821. doi:10.7326/0003-4819-25-5-813
   PubMed Web of Science ®Google Scholar
• Reveno WS, Rosenbaum H. Treatment of hyperthyroidism with 1-methyl-2-mercaptoimidazole. J Am Med Assoc. 1950;143(16):1407–1408. doi:10.1001/jama.1950.02910510025006
   PubMed Web of Science ®Google Scholar
• Corvilain B, Hamy A, Brunaud L, et al. Treatment of adult Graves’ disease. Ann Endocrinol (Paris). 2018;79(6):618–635. doi:10.1016/j.ando.2018.08.003
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Bartalena L, Hegedus L, et al. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7(4):167–186. doi:10.1159/000490384
   PubMed Web of Science ®Google Scholar
• Tsakiridis I, Giouleka S, Kourtis A, et al. Thyroid Disease in Pregnancy: a Descriptive Review of Guidelines. Obstet Gynecol Surv. 2022;77(1):45–62. doi:10.1097/OGX.0000000000000960
   PubMed Web of Science ®Google Scholar
• Illouz F, Luton D, Polak M, et al. Graves’ disease and pregnancy. Ann Endocrinol (Paris). 2018;79(6):636–646. doi:10.1016/j.ando.2018.08.004
   PubMed Web of Science ®Google Scholar
• De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(8):2543–2565. doi:10.1210/jc.2011-2803
   PubMed Web of Science ®Google Scholar
• Li G, Liu Y, Hu H, et al. Evolution of innovative drug R&D in China. Nat Rev Drug Discov. 2022;21(8):553–554. doi:10.1038/d41573-022-00058-6
   PubMed Web of Science ®Google Scholar